Abbott Laboratories

abbott.com

What Do They Do?

Sells medical and diagnostic products, nutrition, and medicines to healthcare providers and institutions, retailers and distributors, and consumers.

How Do They Make Money?

Customers buy healthcare products under short-term receivable arrangements, and product sales occur when goods ship or are delivered. Maintenance and other service agreements earn revenue across their contract term.

revenue

Segment	Share	How money arrives
Established Pharmaceuticals Sold outright	12% FY2022: 11%	Sold outright
Nutritionals Sold outright	19% FY2022: 17%	Sold outright
Diagnostics Sold outright	20% FY2022: 38%	Sold outright
Medical Devices Sold outright	48% FY2022: 34%	Sold outright

Who Are Their Customers?

Healthcare providers and institutions, retailers and wholesalers, and consumers buy Abbott products; Abbott sells directly to many customers and also through distributors, with sales channels varying by product and market.

Do Revenues Turn Into Profits?

Yes. It kept 15 cents of every revenue dollar as net income in FY2025 and turned 17 cents into free cash flow.

Operating income, FY2025

18% of revenue

▲ +18% vs FY2024 ($6.8B, 16%)

Net income, FY2025

15% of revenue

▼ −51% vs FY2024 ($13.4B, 32%)

Free cash flow, FY2025

17% of revenue

▲ +16% vs FY2024 ($6.4B, 15%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +13%; vs $11.1B in Q2 FY2025
Net income: ▼ −48%; vs $1.8B in Q2 FY2025

Medical Devices share of revenue vs 48.2% in Q2 FY2025

Mar 23, 2026 Completed acquisition of Exact Sciences Exact Sciences became a wholly owned subsidiary, adding cancer screening and diagnostics products.

Flat. Revenue was $44.3B in FY2025, about the same as the $43.1B of FY2021.

Broader glucose-monitoring audience The latest report adds the Lingo CGM system for health and wellness alongside FreeStyle systems for people with diabetes.

Biosimilar medicines The Established Pharmaceuticals portfolio extends branded generic medicines with biologic products, including biosimilars in oncology, immunology and women's health.

Revenue over time

Established Pharmaceuticals Nutritionals Diagnostics Medical Devices

$50B$25B$0

FY2021 FY2022 FY2023 FY2024 FY2025

Comments